Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.51 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.50 |
| ▸ | PRCP | P42785 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 2/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13736419 | 0.89 | ADRB2 (0.49) | ADRB2SLC22A1PRCPKDM1ATBXA2R | |
| SCHEMBL13736553 | 0.85 | ADRB2 (0.52) | ADRB2SLC22A1PRCPKDM1ATBXA2R | |
| SCHEMBL13736554 | 0.84 | SLC22A1 (0.56) | ADRB2SLC22A1PRCPKDM1ATBXA2R | |
| SCHEMBL13738596 | 0.82 | ADRB2 (0.47) | ADRB2SLC22A1PRCPKDM1AMEN1 | |
| SCHEMBL13737182 | 0.79 | KDM1A (0.55) | ADRB2SLC22A1PRCPKDM1ATBXA2R | |
| SCHEMBL14152143 | 0.79 | SLC22A1 (0.52) | ADRB2SLC22A1PRCPKDM1ATBXA2R | |
| SCHEMBL13736420 | 0.77 | SLC22A1 (0.50) | ADRB2SLC22A1PRCPKDM1ADRD2 | |
| SCHEMBL13736434 | 0.76 | TBXA2R (0.43) | ADRB2KDM1ATBXA2RDRD2DRD4 | |
| SCHEMBL13736310 | 0.76 | TBXA2R (0.43) | ADRB2KDM1ATBXA2RDRD2DRD4 | |
| SCHEMBL13737898 | 0.76 | SLC22A1 (0.55) | ADRB2SLC22A1PRCPKDM1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309200-B2 | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-04-12 | — | — | US | disclosed |
| US-20120316153-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316153-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC6A11, SLC6A1, KCNB2 | ADRB2 105/4885SLC22A1 611/4885PRCP 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.